Press release
Global Myelodysplastic Syndrome (MDS) Treatment Share 2021 Growth Challenges, Opportunities and Future Trends 2027
The global myelodysplastic syndrome (MDS) treatment market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The major factors that are driving the market growth include a rise in public awareness about myelodysplastic syndromes and their early diagnosis and the availability of new treatment options for MDS. Moreover, early diagnosis of MDS is important, as it significantly increases the quality of life in patients, reducing the chances of recurrent blood transfusion. Increasing regulatory approvals is another factor that is anticipated to fuel the market during the forecast period. For instance, in November 2018, Lupin obtained the US FDA approval of its Decitabine for Injection, 50 mg/vial, single-dose vial, a generic version of Otsuka Pharmaceutical Co. Ltd.'s Dacogen for Injection, 50 mg/vial, single-dose vial. Lupin’s generic version is indicated for the treatment of patients with myelodysplastic syndromes (MDS), which incorporates previously treated and untreated, de novo, as well as secondary MDS of all French-American-British subtypes.To Request a Sample of our Report on Global Myelodysplastic Syndrome (MDS) Treatment Market: https://www.omrglobal.com/request-sample/myelodysplastic-syndrome-mds-treatment-market
Several Drug manufacturing companies and government organizations are focusing more on spreading awareness about the disease by providing funding and conducting awareness programs. For instance, in October 2018, Grupo Biotoscana, a Latin American biopharmaceutical company conducted a campaign for Myelodysplastic Syndrome World Awareness Day, which is celebrated on 25th October. GBT Grupo Biotoscana launched a campaign to raise awareness and educate about the disease throughout the month. Moreover, increasing launch and approval of Azacitidine in some regions is expected to drive the market growth during the forecast period. For instance, in February 2018, BeiGene, Ltd. introduced the commercial availability of VIDAZ (azacitidine for injection) in China. VIDAZA is accredited in China for patients with intermediate-2/excessive-chance myelodysplastic syndrome (MDS), acute myeloid leukaemia (AML) with 20-30% bone marrow blasts, and chronic myelomonocytic leukaemia. It is marketed in China by BeiGene under an exclusive license from Celgene Corp.
Market Coverage
· The market number available for – 2020-2027
· Base year- 2020
· Forecast period- 2021-2027
· Segment Covered
· Regions Covered- Globally
· Competitive Landscape: Celgene Corp., Otsuka Pharmaceutical Co., Ltd., and Dr. Reddy's Laboratories Ltd., among others.
(Get 15% Discount on Buying this Report)
A full Report of Global Myelodysplastic Syndrome (MDS) Treatment Market is Available at: https://www.omrglobal.com/industry-reports/myelodysplastic-syndrome-mds-treatment-market
Global Myelodysplastic Syndrome (MDS) Treatment Market Report by Segment
By Drug
• Azacitidine
• Lenalidomide
• Decitabine
• Deferasirox
Global Myelodysplastic Syndrome (MDS) Treatment Market by Region
North America
· United States
· Canada
Europe
· UK
· Germany
· Spain
· France
· Italy
· Rest of Europe
Asia-Pacific
· India
· China
· Japan
· South Korea
· Rest of APAC
Rest of the World
Reasons to buy from us –
1. We cover more than 15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after purchasing your report.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Global Myelodysplastic Syndrome (MDS) Treatment Share 2021 Growth Challenges, Opportunities and Future Trends 2027 here
News-ID: 2533631 • Views: …
More Releases from Orion Market Research

Infrastructure as Code (IaC) Service Market Size Analysis, Competitive Insights, …
Infrastructure as Code (IaC) Service Market was valued at approximately USD 0.932 billion, and it's projected to expand to around USD 7.509 billion by 2033, achieving a robust CAGR of 23.2% from 2024 to 2033.
Infrastructure as Code (IaC) Service Market Overview
The Infrastructure as Code (IaC) Service Market is experiencing remarkable expansion, fueled by the escalating need for scalable, automated infrastructure deployment across cloud and enterprise environments. In 2023, the market…

Ultra High-Performance Liquid Chromatography (UHPLC) Columns Market : A Guide to …
Ultra High‐Performance Liquid Chromatography (UHPLC) Columns Market is estimated to be valued at USD 2.5 billion, and is projected to grow to approximately USD 4.8 billion by 2033, representing a compound annual growth rate (CAGR) of about 7.8% from 2024 to 2033.
Ultra High-Performance Liquid Chromatography (UHPLC) Columns Market Overview
The UHPLC columns market is on a strong growth trajectory, fueled by increasing demand for rapid, high-resolution analytical techniques across pharmaceuticals, biotechnology,…

Property Management Service Market Rising Demand and Growth Forecast Through 203 …
Property Management Service Market was valued at approximately USD 17.3 billion. It is anticipated to reach around USD 32.0 billion by 2033, growing at a compound annual growth rate (CAGR) of 7.3% from 2024 to 2033.
Property Management Service Market Overview
The Property Management Service Market is witnessing steady growth due to increasing urbanization, rising investments in real estate, and a growing demand for outsourced property management solutions. Property owners are increasingly…

5G Chipset Market Set to Witness Significant Growth by 2033 | Apple Inc., HiSili …
The global 5G chipset market was valued at USD 33.75 billion in 2024 and is projected to reach USD 502.66 billion by 2033, growing at a compound annual growth rate (CAGR) of 35% from 2025 to 2033.
5G Chipset Market Overview
The 5G chipset market is experiencing rapid growth, driven by the global rollout of 5G networks and the increasing demand for high-speed, low-latency connectivity across various applications, including smartphones, IoT…
More Releases for MDS
Prominent Myelodysplastic Syndrome (MDS) Drugs Market Trend for 2025: Innovative …
What Are the Projected Growth and Market Size Trends for the Myelodysplastic Syndrome (MDS) Drugs Market?
The myelodysplastic syndrome (MDS) drugs market has expanded steadily in recent years. It is projected to increase from $3.47 billion in 2024 to $3.73 billion in 2025, reflecting a CAGR of 7.5%. The past growth can be attributed to the aging population, advancements in targeted therapies, ongoing clinical trials, and increased awareness.
The myelodysplastic syndrome (MDS)…
Myelodysplastic Syndrome (MDS) Treatment Market Insights, Forecast to 2031
"Myelodysplastic Syndrome (MDS) Treatment Market 2024,"
The objectives outlined in the report are multifaceted and aimed at offering a comprehensive understanding of the Myelodysplastic Syndrome (MDS) Treatment market dynamics. These objectives encompass a meticulous analysis and forecast of the market's dimensions, encompassing both its value and volume aspects. Additionally, the report seeks to discern and delineate the market shares held by major segments within the Myelodysplastic Syndrome (MDS) Treatment industry, providing stakeholders…
MDS Dental Assisting Academy Brings Flexible Dental Assisting Courses Online
CONTACT:
MDS Dental Assisting Academy
Address: 122 Thicket Lane
City: Freedom
State: California
Postcode: 95019
Country: USA
Telephone: 1-888-637-4732
Website: https://dentalassistanceschool.com/
Email: info@mds4rda.com
California, January 28th, 2022: Are you interested in dentistry? What do you think of a career in dental assisting? If being a dental assistant is your career choice, then an RDA program in MDS Dental Assisting Academy will suit you the best. They provide an interactive course…
CASwell Secures Products Against MDS Attacks
New firmware updates for network devices & servers against ZombieLoad, RIDL & Fallout
Taipei, Taiwan - August 27th, 2019 - CASwell Inc., a leading manufacturer of innovative and high-performance server solutions for SD-WAN (uCPE/vCPE) and network security systems, announced today that most of its network devices and servers have received updates for their firmware or BIOS making them secure against any malicious attacks based on MDS vulnerabilities. With these updates customers…
Myeloidysplastic Syndromes (MDS) – Epidemiology Insights (2016-2028)
Myeloidysplastic syndromes (MDS) can be described as a group of hematologic malignancies, that occurr due to abnormality in blood-forming cells in the bone marrow. It is a rare blood cancer and can be mild, moderate or severe, in terms of severity.
Download the sample report @ https://www.pharmaproff.com/request-sample/1162
This syndrome can be classified into three main types: MDS with single lineage dysplasia wherein a single type of blood cell appears abnormal; multilineage…
Myelodysplastic Syndrome (MDS) Treatment Market Industry Forecast till 2025
Myelodysplastic (MDS) syndrome is a type of bone marrow disorder, where bone marrow is unable to produce healthy and mature blood cells. The immature blood cells called as blasts, get stored in the bone marrow and blood and obstruct the natural function of the hematological system which results in depletion of healthy red blood cells, platelets, and white blood cells. Myelodysplastic syndrome is usually seen in geriatric population and more…